Home Categories Organic Chemistry Abiraterone Acetate
A0788412

Abiraterone Acetate , ≥99% , 154229-18-2

Synonym(s):
17-(Pyridin-3-yl)androsta-5,16-dien-3β-yl acetate;Abiraterone acetate;CB 7598

CAS NO.:154229-18-2

Empirical Formula: C26H33NO2

Molecular Weight: 391.55

MDL number: MFCD00934213

EINECS: 620-314-7

Pack Size Price Stock Quantity
5MG RMB23.20 In Stock
25MG RMB31.20 In Stock
100MG RMB39.20 In Stock
250mg RMB63.20 In Stock
1g RMB127.20 In Stock
5g RMB383.20 In Stock
25g RMB1359.20 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 127-130°C
Boiling point: 506.7±50.0 °C(Predicted)
Density  1.14±0.1 g/cm3(Predicted)
storage temp.  -20°C
solubility  Chloroform (Slightly), DMSO (Sparingly), Methanol (Sparingly)
pka 5.31±0.12(Predicted)
form  powder
color  white to beige

Description and Uses

In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%).

A novel steroidal inhibitor of human Cytochrome P450(17a-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.

Safety

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H360-H372
Precautionary statements  P201-P202-P260-P264-P270-P308+P313
WGK Germany  3
RTECS  BV7992100
HS Code  2937290000

RELATED PRODUCTS